FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of … – Business Wire (press release)
Yahoo Sports |
FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of …
Business Wire (press release) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics … FDA speeds up review of Roche's Tecentriq to treat another bladder cancer |
